Pancreatic cancer, which represents the second largest proportion of cancer types undergoing Japanese precision cancer medicine (https://for-patients.c-cat.ncc.go.jp/registration_status/), develops at a median age of 60 years old (mostly after 50 years old) in CDKN2A variant carriers [7]. Here, CDKN2A is linked to cancer.